
NIH State-of-the-Science Conference Statement on Tobacco Use: Prevention, Cessation, and Control



NIH Consensus and State-of-the-Science Statements

Volume 23, Number 3 June 12–14, 2006

NATIONAL INSTITUTES OF HEALTH
Office of the Director



About the NIH Consensus Development Program

National Institutes of Health (NIH) consensus and state-of-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of 1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ), 2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, 3) questions and statements from conference attendees during open discussion periods that are part of the public session, and 4) closed deliberations by the panel during the remainder of the second day and the morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the federal government.

The statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research, and that the information provided is not a substitute for professional medical care or advice.

Reference Information

For making bibliographic reference to this statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution:

NIH State-of-the-Science Conference Statement on Tobacco Use: Prevention, Cessation, and Control. Ann Intern Med. 2006. 145:839-844.

Publications Ordering Information

NIH Consensus Statements, State-of-the-Science Statements, and Technology Assessment Statements and related materials are available by writing to the NIH Consensus Development Program Information Center, P.O. Box 2577, Kensington, MD 20891; by calling toll free *1-888-NIH-CONSENSUS (888-644-2667)*; or by visiting the NIH Consensus Development Program home page at *http://consensus.nih.gov* on the World Wide Web. When ordering copies of this statement, please reference item number **2006-00029-STMT.**

The Evidence Report prepared for this conference by the Agency for Healthcare Research and Quality is available on the Web via *http://www.ahrq.gov/clinic/tp/tobusetp.htm.* Printed copies may be ordered from the AHRQ Publications Clearinghouse by calling 1-800-358-9295. Requestors should ask for AHRQ Publication No. 06-F015.

NIH State-of-the-Science Conference Statement on

Tobacco Use: Prevention, Cessation, and Control

NIH Consensus and State-of-the-Science Statements

Volume 23, Number 3 June 12–14, 2006

NATIONAL INSTITUTES OF HEALTH
Office of the Director



Disclosure Statement

All of the panelists who participated in this conference and contributed to the writing of this statement were identified as having no financial or scientific conflict of interest, and all signed forms attesting to this fact. Unlike the expert speakers who present scientific data at the conference, the individuals invited to participate on NIH Consensus and State-of-the-Science panels are reviewed prior to selection to assure that they are not proponents of an advocacy position with regard to the topic and are not identified with research that could be used to answer the conference questions.

For more information about conference procedures, please see *http://consensus.nih.gov/aboutcdp.htm*.

Archived Conference Webcast

The NIH State-of-the-Science Conference on Tobacco Use: Prevention, Cessation, and Control was webcast live June 12–14, 2006. The webcast is archived and available for viewing free of charge at http://consensus.nih.gov/previousstatements.htm.

Abstract

Objective

To provide health care providers, patients, and the general public with a responsible assessment of currently available data on tobacco use: prevention, cessation and control

Participants

A non-DHHS, non-advocate 14-member panel included experts in the fields of medicine, general and pediatric psychiatry, addiction medicine, nursing, social work, population science, cancer prevention, minority health and health disparities, clinical study methodology, clinical epidemiology, and a public representative. A listing of the panel members and their institutional affiliations is included in the draft conference statement. In addition, 15 experts from pertinent fields presented data to the panel and conference audience

Evidence

Presentations by experts and a systematic review of the literature prepared by the RTI International-University of North Carolina Evidence-based Practice Center, through the Agency for Healthcare Research and Quality. Scientific evidence was given precedence over anecdotal experience.

Conference Process

The panel drafted its statement based on scientific evidence presented in open forum and on published scientific literature. The draft statement was presented on the final day of the conference and circulated to the audience for comment. The panel released a revised statement later that day at *http://consensus.nih.gov.*This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government.

Conclusions

Tobacco use remains a very serious public health problem. Coordinated national strategies for tobacco prevention, cessation, and control are essential if the United States is to achieve the *Healthy People 2010* goals. Most adult smokers want to quit, and effective interventions exist. However, only a small proportion of tobacco users try treatment. This gap represents a major national quality-of-care problem. Many cities and states have implemented effective policies to reduce tobacco use; public health and government leaders should learn from these experiences.

Because smokeless tobacco use may increase in the United States, it will be increasingly important to understand net population harms related to use of smokeless tobacco. Prevention, especially among youth, and cessation are the cornerstones of strategies to reduce tobacco use. Tobacco use is a critical and chronic problem that requires close attention from health care providers, health care organizations, and research support organizations.

Introduction

Tobacco use is the leading preventable cause of premature death in the United States. Each year, more than 440,000 Americans die of tobacco-related disease, accounting for 1 in every 5 deaths. Cigarette smoking is responsible for more than 30 percent of cancer deaths annually in the United States. Smoking also contributes substantially to deaths from heart disease, stroke, and chronic obstructive pulmonary disease. According to current estimates, 21 percent of American adults (44.5 million individuals) and 22 percent of American high school students (3.75 million individuals) smoke. Cigarettes are the predominant form of tobacco that Americans consume, but tobacco consumption also includes smokeless tobacco, cigars. and pipes. In addition to the toll in human lives, tobacco use is an enormous economic burden on society. From 1995 to 1999, estimated annual smoking-attributable economic costs in the United States were \$75.5 billion for direct medical care for adults and \$81.9 billion for lost productivity.

Tobacco use per capita has decreased from about 14 pounds per year in the 1950s to about 5 pounds per year in 2000, suggesting that public health interventions have been effective. Yet it is unlikely that the United States will reach the *Healthy People 2010* objectives of reducing smoking prevalence to 12 percent or less in adults and 16 percent or less in youth. Further progress in reducing tobacco use is an important challenge facing the public health, medical, and political communities.

For these reasons, the National Cancer Institute and the NIH's Office of Medical Applications of Research sponsored a State-of-the-Science Conference on Tobacco Use: Prevention, Cessation, and Control on June 12–14, 2006 in Bethesda, Maryland. The key questions to be addressed at the State-of-the-Science Conference were:

 What are the effective population- and communitybased interventions to prevent tobacco use in adolescents and young adults, including among diverse populations?

- What are the effective strategies for increasing consumer demand for and use of proven, individually oriented cessation treatments, including among diverse populations?
- What are the effective strategies for increasing the implementation of proven, population-level, tobacco-use cessation strategies, particularly by health care systems and communities?
- What is the effect of smokeless tobacco product marketing and use on population harm from tobacco use?
- What is the effectiveness of prevention and of cessation interventions in populations with co-occurring morbidities and risk behaviors?
- What research is needed to make the most progress and greatest public health gains nationally and internationally?

At the conference, invited experts presented information pertinent to these questions, and a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ) was summarized. The evidence report (http://www.ahrq.gov/clinic/tp/tobusetp.htm) emphasized randomized, controlled trials; systematic reviews; and other experimental or observational studies with more than 100 participants. During the conference, attendees provided both oral and written statements in response to the key questions. The panel members weighed this evidence as they addressed the key conference questions.

1. What are the effective populationand community-based interventions to prevent tobacco use in adolescents and young adults, including among diverse populations?

Never starting to use tobacco is a much better strategy than having to stop. Tobacco use usually begins primarily during adolescence. Almost 25 percent of 12th-graders have smoked in the previous 30 days, and almost all adult daily smokers have tried cigarettes before age 18 years. Research reports suggest a flattening of the past decade's downward trend in adolescent smoking. Adolescents (13 to 18 years of age) and young adults (18 to 24 years of age) are susceptible to cultural influences, including family, friends, peers, media, community, and tobacco marketing influence. Gender, racial/ethnic background, socioeconomic status, geography, and sexual orientation all influence tobacco use and the effectiveness of strategies to prevent it, which means that many preventive strategies are needed.

What We Know

Previous reviews have identified three effective general population approaches to preventing tobacco use in adolescents and young adults: 1) increased prices through taxes on tobacco products; 2) laws and regulations that prevent young people from gaining access to tobacco products, reduce their exposure to tobacco smoke, and restrict tobacco industry advertising; and 3) mass media campaigns. Previous reviews show that school-based intervention programs aimed at preventing tobacco use in adolescents are effective in the short term. Comprehensive statewide programs have also reduced overall tobacco use in young adults.

What We Need to Learn

Although previous evidence shows that clean indoor air and youth access policies reduce adolescent smoking rates, we need to know more about the effectiveness of these policies in specific populations. The evidence that culturally sensitive programs are more effective in reducing smoking among adolescents and young adults is not adequate to support a firm conclusion. We need to develop school-based strategies that lead to sustained reduction in starting to use tobacco.

2. What are the effective strategies for increasing consumer demand for and use of proven, individually oriented cessation treatments, including among diverse populations?

About 70 percent of the 44.5 million adult smokers in the United States want to quit, but of those who try to quit in a given year, fewer than 5 percent succeed. Effective treatments can double or triple quit rates, but too few smokers try these interventions and too few physicians offer them.

What We Know

Previous systematic reviews identified effective strategies for increasing use of the following proven individually oriented cessation treatments.

A mass media education campaign uses brief, recurring messages to inform and to motivate tobacco product users to quit. It is effective in increasing tobacco use cessation when combined with other interventions.

For example, media messages that direct viewers to call for further information or support increase use of telephone-based tobacco cessation information or support services.

Proactive telephone smoking cessation support occurs when the health care provider initiates contact with the smoker. Advice to stop smoking is effective, especially when combined with other interventions, such as educational approaches or pharmacologic therapies.

Increasing the unit price for tobacco products increases tobacco use cessation and reduces consumption regardless of the smoker's ethnicity, gender, and socioeconomic status.

Reducing out-of-pocket costs for effective cessation therapies—for example, because health insurance pays for the service—increases their use. Making smokers aware of their health insurance's coverage policy can increase use of smoking cessation treatments.

Culturally tailored, gender-specific, and languageappropriate programs show promise.

What We Need to Learn

Generic interventions may be less effective than interventions tailored to specific populations, so we need to understand how to best tailor interventions. To increase demand for treatments, smokers must want them, expect them, and ask for them. We need to learn how to make treatments more attractive to tobacco users. We need to create a sustained demand for effective treatments.

3. What are the effective strategies for increasing the implementation of proven, population-level tobacco use cessation strategies, particularly by health care systems and communities?

Despite strong evidence that a variety of pharmacologic and behavioral interventions increase tobacco cessation, only a small proportion of tobacco users ever try them. Strategies that target individual tobacco users may be effective but fail to reach most smokers. Community-level strategies target broad geographic populations (for example, cities) or smaller, more localized groups of people (for example, military bases, colleges). Clinical settings in which to implement community-level strategies range in scope from individual practices to large integrated organizations.

What We Know

Community-based interventions aim to increase demand for cessation interventions (media campaigns, higher prices, smoke-free environments) or facilitate access to cessation services (community-level quit lines, offering cessation services in community settings). Evidence suggests that media campaigns, telephone-counseling programs (quit lines), and increases in tobacco pricing and taxation are effective. Providing cessation services in nonclinical community settings shows some promise, but the literature lacks good evidence of community setting interventions in the United States. Controlled trials showed that community-based self-help materials alone were ineffective.

Smoking cessation interventions at the health care system level are effective according to fair to good evidence. These approaches can target patients, providers, or both. Strong evidence supports the effectiveness of financial incentives, including reducing out-of-pocket costs for cessation interventions and reimbursing providers for providing cessation services. Other economic strategies, such as discounts on insurance premiums for nonsmokers, are untested. Effective health system-level educational and organizational approaches include routine questioning about smoking, provider education, academic detailing, reminders, audit, and feedback, However, these approaches appear most effective when several of them are used in combination. Provider education or feedback is ineffective when used in isolation. Published studies have used physician and nonphysician providers (nurses, dentists, orthodontists, social workers, psychologists, and pharmacists) to effectively deliver cessation services. According to good evidence, health systems with dedicated staff for tobacco cessation services achieve better outcomes than those that do not designate specific staff for this function. Strategies that institutionalize cessation services in health settings (for example, brief interventions for every primary care patient, mandatory counseling for tobacco users before hospital discharge) increase use of cessation services.

Observational evidence suggests that measuring the quality of hospital (Joint Commission on Accreditation of Healthcare Organizations) or organization-related (Health Plan Employer Data and Information Set) tobacco cessation efforts may increase their delivery.

What We Need to Learn

We need to understand why effective strategies. such as smoke-free environments, pricing and taxes, media campaigns, and insurance coverage of cessation interventions, are not disseminated more widely and how to overcome barriers to their implementation. Published studies have not systematically identified organizational features of health care systems that facilitate routine delivery of tobacco cessation services. System-level approaches differ. For example, telephone counseling programs vary in intensity, referral sources, and inclusion of pharmacotherapy. Many studies have used multimodal, bundled services. We need detailed information about the features of a smoking cessation strategy that are critical to its success. We lack evidence about the interaction of simultaneous efforts to increase tobacco cessation. What combinations of health system strategies are most successful? What are the kev interactions between community-based and health systems-based approaches? How do stepped-care approaches or the availability of electronic health records influence the uptake of cessation services? We need to measure the effectiveness of delivering smoking cessation services in non-clinical settings, such as stores. religious organizations, and workplaces in the United States

4. What is the effect of smokeless tobacco product marketing and use on population harm from tobacco use?

New products and aggressive marketing may increase the use of smokeless tobacco in the United States at a time when questions have been raised about the overall population benefits and harms of smokeless tobacco. Use of any tobacco product must be discouraged. Yet some have argued that substituting smokeless tobacco for smoking may decrease overall population harm. Whether this assertion is true depends on the answers to two questions: 1) Does smokeless tobacco marketing cause smokers to benefit by substituting these products for cigarettes? and 2) Does smokeless tobacco marketing cause nonusers to start using tobacco products, which are addictive, are harmful in their own right, and may lead to smoking?

A wide range of smokeless tobacco products is available, and companies are developing new products. Chewing tobacco and snuff are widely available in the United States. These products vary in their content of nicotine, carcinogens, and other toxins. Newer smokeless tobacco products may contain lower levels of nicotine and nitrosamines. These new products may be targeted to specific groups, such as young adults, athletes, and women, and may have broader consumer appeal because of use of flavorings and new delivery methods, such as small pouches or lozenges that eliminate the need for spitting.

Previous reviews describe the health risks of smokeless tobacco (including cancer of the oral cavity and pharynx, oral and periodontal disease, tooth decay, and pregnancy-related health problems). The range of risks, including nicotine addiction, from smokeless tobacco products may vary extensively because of differing levels of nicotine, carcinogens, and other toxins in different products. It is unclear whether newer products—with presumed lower levels of these substances—carry substantially lower health risks.

What We Know

The evidence report included no previous systematic reviews that directly addressed the net population effects of smokeless tobacco marketing. However, two fair-quality observational studies shed some light on whether the marketing of smokeless tobacco causes smokers to substitute smokeless tobacco for smoking, causes nonusers to take up smokeless tobacco, or serves as a gateway to smoking.

One cross-sectional study of young male adolescents in the United States reported that those who recalled smokeless tobacco advertisements were seven times more likely than those who did not recall such advertisements to be current users of smokeless tobacco. A population-based cohort study of boys 11 to 19 years of age reported that males who were nonsmokers at baseline but had been regular users of smokeless tobacco were more than three times as likely as never users of smokeless tobacco to be smokers during four years of follow-up. These studies do not support the hypothesis that smokeless tobacco reduces harm

What We Need to Learn

The paucity of evidence about smokeless tobacco in the United States leaves many questions unanswered. Scandinavian studies do not reflect the range of smokeless tobacco products used or the diverse populations exposed to these products in the United States. It is therefore difficult to extrapolate the findings to the U.S. population. Data about the effectiveness of smokeless tobacco in facilitating smoking cessation and associated population harm reduction are very limited. High-quality studies comparing smokeless tobacco with proven pharmacologic and behavioral cessation interventions would help to inform national public health strategy about smokeless tobacco.

5. What is the effectiveness of prevention and of cessation interventions in populations with co-occurring morbidities and risk behaviors?

In addition to adverse health consequences of smoking, continued smoking among individuals who have psychiatric and physical conditions can lead to progression of these conditions and can complicate their treatment. Individuals who have mood disorders. psychoses, anxiety disorders, developmental disorders, and substance use disorders are more likely to be addicted to nicotine than people without these disorders. For example, approximately 90 percent of individuals with diagnoses of schizophrenia are smokers. Chronic diseases, such as asthma, diabetes, cardiovascular disease, cancer, and HIV/AIDS, are particularly susceptible to the adverse impact of tobacco exposure. Although pregnancy is not an illness, it is another condition in which tobacco use is harmful. The benefit of smoking cessation in people who have these conditions is particularly high.

Smokers with HIV infection who quit are more likely to respond well to HIV treatment and are less likely to die than HIV-infected smokers who continue to smoke. Benefits of smoking cessation after cancer diagnosis include decreased risk for treatment complications, decreased risk for second primary tumors, improved survival rates, and improved quality of life.

What We Know

Persons with psychiatric conditions can stop smoking using standard pharmacologic and behavioral interventions but seldom achieve long-term abstinence. However, tobacco cessation counseling or cognitive behavioral therapy alone was not effective for adults with a history of major depressive disorder (MDD). Individuals who have a history of MDD may have more difficulty quitting smoking and more severe nicotine withdrawal symptoms than those who do not have MDD. Similarly, motivational interviewing or brief advice about tobacco cessation was not effective for adolescents hospitalized for psychiatric and substance use problems. A meta-analysis showed that smoking cessation interventions are effective in people with substance abuse conditions. Moreover. quitting tobacco does not increase the risk for relapse of other co-occurring addictions. The findings support past recommendations that counseling and pharmacotherapy have positive short-term effects, but the body of evidence is insufficient to draw clear conclusions.

In persons who have medical comorbid conditions, successful tobacco cessation treatments have statistically significantly reduced smoking prevalence compared with control participants. Reviews of randomized, controlled trials conclude that combination treatment (pharmacologic and behavioral interventions) is superior to either intervention alone.

In general, pregnant women have a high rate of attempts to quit and a low rate of success. However, smoking cessation treatment is effective for highly motivated. interested women who have a low level of nicotine addiction, and quitting improves pregnancy outcome. Unfortunately, the evidence documents high rates of relapse at 6 to 12 months postpartum.

What We Need to Learn

We do not know whether tailored, multimodal smoking cessation interventions for people with psychiatric comorbid conditions will reduce the exacerbation of symptoms that typically occurs with current pharmacologic smoking cessation interventions. We need more information to address the benefits and risks of long-term nicotine replacement in patients who have psychiatric disorders.

No information was presented to the panel about interventions to prevent individuals who have comorbid physical conditions from starting to smoke. Randomized, controlled trials of smoking cessation have not examined results for subgroups of individuals who have physical comorbid conditions. Therefore, we lack information about the relative effectiveness of tobacco cessation interventions in these subgroups. We lack information about whether tailoring tobacco cessation interventions will increase their effectiveness in patients with comorbid disease.

We lack information about the appropriate timing of the initiation of tobacco cessation interventions in relationship to treatment of psychiatric and physical comorbid conditions. Further research is also needed to address the benefits and risks of long-term nicotine replacement in patients who have psychiatric disorders or are pregnant. We do not know if extended counseling for tobacco cessation during pregnancy is effective and whether pharmacotherapy affects fetal development. We have intriguing but limited information about genetic predisposition to tobacco addiction and benefit from treatment in people so disposed.

6. What research is needed to make the most progress and greatest public health gains nationally and internationally?

The following list identifies issues that the panel considers priority aims for future research and public health efforts.

Improve and Implement Effective Interventions

Understand the role of different media in increasing consumer demand for and use of effective, individually oriented tobacco cessation treatments for diverse populations.

Identify and reduce barriers faced by providers, insurers, policymakers, and others to implementing effective strategies to increase and sustain demand for smoking cessation treatment

Examine the effectiveness of different components of telephone-based counseling programs (for example, population quit lines versus provider-associated programs, self-referral versus provider referral to telephone-based counseling, bundling of services within programs).

Develop and enhance pharmacologic and nonpharmacologic treatments.

Improve and Implement Effective Policies

Increase policymakers' and the public's awareness of effective strategies for preventing tobacco use, promoting tobacco cessation, and decreasing harm from environmental tobacco exposure.

Identify and overcome barriers to implementing successful comprehensive statewide tobacco control programs, such as those used in California and Florida.

Develop effective policies for reimbursing health care providers for offering tobacco cessation interventions.

Develop New Population- and Community-Based Interventions

Improve school-based interventions to prevent students from starting to use tobacco. Potential improvements might include targeting programs to diverse populations, starting programs in elementary schools, and expanding after-school programs.

Determine the effectiveness of implementing interventions in settings other than schools and health care facilities, such as homes, community organizations, religious institutions, pharmacies, stores, bars, workplaces, military institutions, and correctional institutions.

Determine the effectiveness of incorporating social context (for example, culture, neighborhoods, and social networks) in interventions to prevent or stop tobacco use.

Evaluate the long-term effects of social marketing strategies on tobacco use, particularly media-based programs to counter tobacco advertising.

Evaluate approaches to reduce tobacco use in populations that are particularly vulnerable or where tobacco has a disproportionately adverse effect, including people who have co-occurring conditions; racial and ethnic minorities; people who have low socioeconomic status; people who have limited English proficiency; people who have low levels of health literacy; and lesbian, gay, bisexual, and transgender populations.

Learn from "natural experiments" that result from implementation of new policies on pricing/taxation, smoke-free environments, or restrictions on the availability of tobacco products.

Evaluate the effectiveness of chronic care models for increasing smoking cessation.

Evaluate the effectiveness of public performance measures (for example, publicly reported qualityof-care report cards) and financial incentives for increasing smoking cessation.

Infrastructure

Promote surveillance programs that track tobacco use (initiation, quitting, intensity of smoking, use of smokeless tobacco); use of treatment; motivation to quit; new products; and marketing, policy, and systems changes.

To facilitate comparison of research studies, standardize definitions and methods to describe tobacco use status, interventions, processes, and outcomes so that studies may be compared more readily. Encourage economic studies of tobacco prevention, cessation, and control.

Educate providers, including physicians, dentists, nurses, and allied health professionals about the importance of tobacco-related diseases and the availability and delivery of effective interventions.

Smokeless Tobacco

Conduct research on the impact of marketing of smokeless tobacco on tobacco use and tobacco-related health effects in smokers and nonsmokers. This research is especially important in vulnerable populations.

Measure the levels of nicotine and other toxins in various smokeless tobacco products to better understand their potential health risks.

Evaluate advantages and disadvantages of regulating smokeless tobacco in a manner similar to medicinal nicotine.

Assess the risks of cancer and other diseases related to current smokeless tobacco products.

Conclusions

Tobacco use remains a very serious public health problem. Coordinated national strategies for tobacco prevention, cessation, and control are essential if the United States is to achieve the *Healthy People 2010* goals. Most adult smokers want to quit, and effective interventions exist. However, only a small proportion of tobacco users try treatment. This gap represents a major national quality-of-care problem. Many cities and states have implemented effective policies to reduce tobacco use; public health and government leaders should learn from these experiences.

Because smokeless tobacco use may increase in the United States, it will be increasingly important to understand net population harms related to use of smokeless tobacco. Prevention, especially among youth, and cessation are the cornerstones of strategies to reduce tobacco use. Tobacco use is a critical and chronic problem that requires close attention from health care providers, health care organizations, and research support organizations.

State-of-the-Science Panel

David F. Ransohoff, M.D.

Panel and Conference Chairperson Professor of Medicine School of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina

Marshall H. Chin, M.D., M.P.H.

Panel and Conference Co-chairperson Associate Professor of Medicine University of Chicago Chicago, Illinois

Frederic C. Blow, Ph.D.

Director
Serious Mental Illness
Treatment Research
and Evaluation Center
Ann Arbor Veterans
Administration
Medical Center
Associate Professor
Department of Psychiatry
University of Michigan
Medical School
Ann Arbor, Michigan

Bernadine Cimprich, Ph.D., R.N., F.A.A.N.

Associate Professor, Nursing University of Michigan Ann Arbor, Michigan

Lawrence Friedman. M.D.

Independent Consultant Rockville, Maryland

Christine Laine, M.D., M.P.H.

Senior Deputy Editor Annals of Internal Medicine Clinical Associate Professor Jefferson Medical College Philadelphia, Pennsylvania

William F. Renn, M.S.W., L.C.S.W., L.C.A.S., C.C.S.

Associate Professor
Department of Psychiatry
University of North Carolina
School of Medicine
Director
University of North Carolina
Health Care's Alcohol and
Substance Abuse Program
Chapel Hill, North Carolina

Elena V. Rios, M.D., M.S.

President and CEO
National Hispanic
Medical Association
Washington, DC

Mary E. Ropka, Ph.D., R.N., F.A.A.N.

Associate Member Division of Population Science Fox Chase Cancer Center Philadelphia, Pennsylvania

Anita L. Sabichi, M.D.

Associate Professor
Department of Clinical
Cancer Prevention
University of Texas M.D.
Anderson Cancer Center
Houston, Texas

Marilou G. Tablang-Jimenez, M.D.

General and Child Adolescent Psychiatry Germantown, Maryland

Stephen B. Thomas, Ph.D.

Director
Center for Minority Health
Philip Hallen Professor of
Community Health and
Social Justice
Graduate School of
Public Health
University of Pittsburgh
Pittsburgh, Pennsylvania

Nancy S. Thomason

Founder and President
Oklahoma Brain
Tumor Foundation
Oklahoma City, Oklahoma

Claudette Varricchio, D.S.N., R.N., F.A.A.N.

Independent Consultant Rockville, Maryland

Speakers

Lourdes Baezconde-Garbanati, Ph.D., M.P.H.

Director, Hispanic/Latino Tobacco Education Partnership and Southern California Cancer Information Services Partnership Program Office (CIS) Institute for Health Promotion and Disease Prevention Research and Norris Comprehensive Cancer Center Department of Preventive Medicine Keck School of Medicine University of Southern California Alhambra, California

Elizabeth M. Barbeau, Sc.D., M.P.H.

Associate Professor
Dana Farber Cancer Institute
Harvard School of Public Health
Boston, Massachusetts

Michael C. Fiore, M.D., M.P.H.

Professor of Medicine Director, UW-Center for Tobacco Research and Intervention University of Wisconsin Madison, Wisconsin

Jean Forster, Ph.D., M.P.H.

Professor
Division of Epidemiology
and Community Health
University of Minnesota
Minneapolis, Minnesota

Phillip Gardiner, Ph.D.

Social and Benavioral Sciences Research Administrator University of California Oakland, California

Gary A. Giovino, Ph.D., M.S.

Senior Research Scientist
Director, Tobacco Control
Research Program
Division of Cancer Prevention
and Population Sciences
Department of Health Behavior
Roswell Park Cancer Institute
Buffalo, New York

Ellen R. Gritz. Ph.D.

Olla S. Stribling Distinguished Chair for Cancer Research Professor and Chair, Department of Behavioral Science University of Texas M.D. Anderson Cancer Center Houston, Texas

Sharon M. Hall, Ph.D.

Professor in Residence, Psychiatry University of California, San Francisco San Francisco, California

Dorothy Hatsukami, Ph.D.

Professor University of Minnesota Minneapolis, Minnesota

Lynn T. Kozlowski, Ph.D.

Professor and Head
Department of
Biobehavorial Health
Pennsylvania State University
University Park, Pennsylvania

Tim McAfee, M.D., M.P.H.

Chief Medical Officer Free & Clear Seattle, Washington

Cathy L. Melvin, Ph.D., M.P.H.

Senior Research Fellow
and Director Child Health
Services Research
Cecil G. Sheps Center for
Health Services Research
Research Associate Professor
Department of Maternal and
Child Health
School of Public Health
University of North Carolina
at Chapel Hill
Chapel Hill, North Carolina

C. Tracy Orleans, Ph.D.

Distinguished Fellow and Senior Scientist Robert Wood Johnson Foundation Princeton, New Jersey

Eliseo Perez-Stable, M.D.

Professor of Medicine University of California, San Francisco San Francisco, California

John P. Pierce, Ph.D.

Sam M. Walton Professor for Cancer Research University of California, San Diego La Jolla, California

Leah M. Ranney, Ph.D., M.A.

Research Fellow and Research Associate Cecil G. Sheps Center for Health Services Research University of North Carolina at Chapel Hill Chapel Hill, North Carolina

Robert A. Schnoll, Ph.D.

Assistant Professor
Transdisciplinary Tobacco
Use Research Center
Department of Psychiatry
University of Pennsylvania
Philadelphia, Pennsylvania

Scott L. Tomar, D.M.D., Dr.P.H.

Associate Professor and Chair
Department of Community
Dentistry and Behavioral
Science
University of Florida,
College of Dentistry
Gainesville, Florida

Planning Committee

Scott J. Leischow. Ph.D.

Planning Committee
Chairperson
U.S. Department of Health
and Human Services
Washington, DC
and
Branch Chief
Tobacco Control Research
Branch
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

David Ashley. Ph.D.

Senior Scientist Officer
Centers for Disease Control
and Prevention
Atlanta, Georgia

David Atkins, M.D., M.P.H.

Chief Medical Officer
Center for Practice and
Technology Assessment
Agency for Healthcare
Research and Quality
Rockville, Maryland

Cathy L. Backinger, Ph.D., M.P.H.*

Tobacco Control
Research Branch
Behavioral Research Program
Division of Cancer Control
and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
* Institute Coordinator as of 5/05

Rosalind A. Breslow, Ph.D., M.P.H.

Epidemiologist
Division of Biometry
and Epidemiology
Division of Epidemiology and
Prevention Research
National Institute on Alcohol
Abuse and Alcoholism
National Institutes of Health
Bethesda, Maryland

Patricia S. Bryant, Ph.D.

Health Scientist Administrator
Behavioral and Social Science
Research Program
Clinical Research Branch,
Division of Clinical
Research and
Health Promotion
National Institute of Dental
and Craniofacial Research
National Institutes of Health
Bethesda, Maryland

Allison Chausmer. Ph.D.

Translational Research Branch National Institute on Drug Abuse National Institutes of Health Bethesda, Maryland

Monique Ernst, M.D., Ph.D.

Section of Developmental and Affective Neuroscience National Institute of Mental Health National Institutes of Health Bethesda, Maryland

Kenneth Fink, M.D., M.G.A., M.P.H.

Director
Evidence-based Practice
Centers Program
Center for Outcomes
and Evidence
Agency for Healthcare
Research and Quality
Rockville, Maryland

Gary A. Giovino, Ph.D., M.S.

Senior Research Scientist
Director, Tobacco Control
Research Program
Division of Cancer Prevention
and Population Sciences
Department of Health Behavior
Roswell Park Cancer Institute
Buffalo, New York

Martha L. Hare, Ph.D., R.N.

Program Director
National Institute of
Nursing Research
National Institutes of Health
Bethesda, Maryland

Lynne M. Haverkos, M.D., M.P.H.

Medical Officer
National Institute of
Child Health and
Human Development
National Institutes of Health
Bethesda, Maryland

Jack E. Henningfield, Ph.D.

Professor of Behavioral Biology
Department of Psychiatry
and Behavioral Sciences
Vice President, Research
and Health Policy
Pinney Associates
Bethesda, Maryland

Jared B. Jobe, Ph.D.

Health Scientist Administrator
National Heart, Lung, and
Blood Institute
National Institutes of Health
Bethesda, Maryland

Gary King, Ph.D.

Associate Professor Biobehavioral Health Pennsylvania State University University Park, Pennsylvania

Barnett S. Kramer, M.D., M.P.H.

Director
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Kelli K. Marciel, M.A.

Communications Director
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Colleen M. McBride, Ph.D.

Chief, Social & Behavioral Research Branch National Human Genome Research Institute National Institutes of Health Bethesda, Maryland

Ernestine Murray, R.N., M.A.S.

Captain
U.S. Public Health Service
Senior Health Policy Analyst
Senior Advisor on Tobacco Use
Center for Outcomes
and Evidence
Agency for Healthcare
Research and Quality
Rockville, Maryland

C. Tracy Orleans, Ph.D.

Distinguished Fellow and Senior Scientist Robert Wood Johnson Foundation Princeton, New Jersey

Terry F. Pechacek, Ph.D.

Associate Director for Science
Office on Smoking and Health
Centers for Disease Control
and Prevention
Atlanta, Georgia

Aron Primack, M.D.

John E. Fogarty International Center National Institutes of Health Bethesda, Maryland

Cynthia A. Rooney

Senior Advisor for Consensus Development Office of Medical Applications of Research Office of the Director National Institutes of Health Bethesda, Maryland

Susan Rossi, Ph.D., M.P.H.

Deputy Director
Office of Medical Applications
of Research
Office of the Director
National Institutes of Health
Bethesda, Maryland

Charlotte A. Schoenborn, M.P.H.

Health Statistician
National Center for
Health Statistics
Centers for Disease Control
and Prevention
Hyattsville, Maryland

Ed Trapido, Sc.D.

Associate Director
Epidemiology and
Genetics Program
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Tatiana M. Foroud, Ph.D.*

Associate Professor
Director, Hereditary
Genomics Division
Department of Medical
and Molecular Genetics
Indiana University
School of Medicine
Indianapolis, Indiana
* Panel and Conference
Chairperson through
03/31/06

Conference Sponsors

National Cancer Institute

John E. Niederhuber, M.D. Acting Director, NCI, and Deputy Director for Translational and Clinical Sciences

Office of Medical Applications of Research

Barnett S. Kramer, M.D., M.P.H. *Director*

Conference Cosponsors

Fogarty International Center

Roger I. Glass, M.D., Ph.D. Director

National Heart, Lung, and Blood Institute

Elizabeth G. Nabel, M.D. Director

National Human Genome Research Institute

Francis S. Collins, M.D., Ph.D. *Director*

National Institute of Child Health and Human Development

Duane Alexander, M.D. *Director*

National Institute of Dental and Craniofacial Research

Lawrence A. Tabak, D.D.S., Ph.D. Director

National Institute of Mental Health

Thomas R. Insel, M.D. *Director*

National Institute of Nursing Research

Patricia A. Grady, Ph.D., R.N., F.A.A.N. Director

National Institute on Alcohol Abuse and Alcoholism

Ting-Kai Li, M.D. *Director*

National Institute on Deafness and Other Communication Disorders

James F. Battey, Jr., M.D., Ph.D. Director

National Institute on Drug Abuse

Nora D. Volkow, M.D. *Director*

Office of Behavioral and Social Sciences Research

David B. Abrams, Ph.D. *Director*

Office of Research on Women's Health

Vivian W. Pinn, M.D. *Director*

Conference Partners

Administration for Children and Families, DHHS

Wade F. Horn, Ph.D. Assistant Secretary for Children and Families (ACF)

Centers for Disease Control and **Prevention**, DHHS

Julie Gerberding, M.D., M.P.H. Director

Health Resources and Services Administration, DHHS

Elizabeth M. Duke, Ph.D. *Administrator*

Indian Health Service, DHHS

Charles W. Grim, D.D.S., M.H.S.A. *Director*

National Guideline Clearinghouse, AHRQ, DHHS

Jean Slutsky, P.A., M.S.P.H. *Project Officer*

U.S. Department of Veterans Affairs

R. James Nicholson Secretary